INTRODUCTION
============

Breast cancer is a serious disease among women and has become increasingly prevalent worldwide \[[@B1]\]. Triple-negative breast neoplasm (TNBN) account for 15% to 20% of breast cancers, and is intractable to treatment owing to its poor prognosis and high recurrence rate \[[@B2][@B3]\]. Over the years, a great deal of effort has been expended to enhance the efficacy of TNBN treatments using the angiogenesis inhibitors bevacizumab and paclitaxel; however, this remains only in the developmental stage \[[@B4]\]. Therefore, it is very important to better understand the physiology of TNBN. There are many methods available to identify and understand the physiology of cancers from the gene viewpoint, such as differentially expressed gene (DEG) analysis, and gene clustering and classification. However, these methods have limitations in identifying gene-gene interactions and connections. In addition, gene clustering and classification do not detect important genes in formed clusters.

Given these limitations, we attempted to construct a TNBN gene regulatory network using gene expression data. Previously, de Matos Simoes and Emmert-Streib \[[@B5]\] proved the utility of gene expression data for constructing a gene regulatory network of breast cancer via the BC3Net method, and found significant pathways enriched for the cell cycle and immune response \[[@B6]\]. However, in contrast to their method, we used conditional independence graphs with least absolute shrinkage and selection operator (LASSO) regression to exclude falsely detected gene regulatory networks. By doing this, we created a more precise network to identify gene-gene interactions and hub genes. In addition, we used triple-positive breast neoplasm (TPBN) gene expression data to compare with the TNBN gene regulatory network data, although TPBN is not a definitive entity of breast cancer.

METHODS
=======

We retrieved RNA-Seq expression data for breast cancer from The Cancer Genome Atlas (TCGA) \[[@B7]\]. By definition, in terms of immunohistochemistry, TNBN is negative for the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), whereas TPBN is positive for all three receptors \[[@B7]\].

Data characteristics
--------------------

Of the 1,088 patients with breast cancer logged in TCGA, 115 (10.6%) had TNBN and 97 (8.9%) had TPBN ([Table 1](#T1){ref-type="table"}). The mean age of the patients with TNBN was 54.73 years (range, 42.94--66.52 years), being statistically significantly lower than that of the patients with TPBN, which was 59.98 years (range, 45.88--74.08 years) (*p*=0.004, Student t-test). Of the combined TNBN and TPBN groups, 190 patients were alive and 22 patients were deceased at the time of study. The proportions of pathologic tumor stages were similar in both groups, with stage II being the most frequent followed by stages III and I. Most patients did not receive neoadjuvant chemotherapy, but they also did not have a surgical margin status. Differences in neoadjuvant chemotherapy and surgical margin status were not statistically significant between the two groups (*p*\>0.05, generalized Fisher exact test). RNA-Seq V2 expression levels (log2-transformed and normalized RNASeq by expectation--maximization values) were retrieved from the TCGA portal.

Statistical analyses
--------------------

The statistical analyses involved a two-stage analytical scheme: (1) regression-based network inference and (2) post hoc analysis. In the first stage, we estimated probabilistic neighbors (typically called a conditional independence graph) on the basis of gene expression in the triple-positive and triple-negative patients, respectively. We used LASSO regression to estimate the probabilistic neighbors, applying the optimal penalty parameter to control the probability of including falsely estimated neighbors \[[@B8][@B9]\]. The LASSO-based approach estimates a network by finding probabilistic neighbors around each node, and is computationally efficient and requires only a small amount of memory in computing systems. Thus, this approach is very applicable to such high-dimensional data. The estimated neighbors indicate functional interactions between genes. After that, we calculated the degree of each gene (called the hub gene) and the number of neighboring genes around the hub genes. Subsequently, we sorted the hub genes by degree from large to small, and performed a post hoc analysis to understand their biological functions. In the second stage, both univariate and multivariate Cox proportional hazard models were used to assess survival rates related to hubgene expression. The age, pathologic tumor stage, and ER, PR, and HER2 status were used as covariates to adjust the univariate factor in the survival model. In addition, DEGs between TNBN and TPBN were selected by performing empirical Bayes moderated t-statistics on the log2-transformed RNA-Seq data, with cutoff thresholds of Bonferroni corrected *p*-values of \<0.05 and log fold changes of \>\|1\|, using the Bioconductor 'limma' R-package (<http://bioconductor.org/packages/release/bioc/html/limma.html>) \[[@B10][@B11]\]. For the network statistical analyses, NodeXL version 1.0.1.361 (The Social Media Research Foundation, Belmont, USA) was used.

RESULTS
=======

In the TNBN gene regulatory network, a total of 10,237 vertices and 17,773 edges were observed. The graph density was 0.0003, the maximum vertex-to-vertex distance was 28, and the average vertex-to-vertex distance was 8.6, which means that if one were to go through eight vertices, all would be connected. Statistical results for the TPBN gene regulatory network were similar ([Table 2](#T2){ref-type="table"}).

In the network centrality analysis, the TNBN gene regulatory network revealed the genes *RAPGEF6*, *GTF2A1*, and *ASXL2* to have the highest hub vertex degree with 38 edges ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). In addition, we conducted a hub vertex analysis with the betweenness centrality and eigenvector centrality. *ZDHHC20* had the highest value (2593718.407) for the betweenness centrality, whereas *ASXL2* had the highest value (0.019) for the eigenvector centrality.

For the network clustering analysis, we used the Clauset-Newman-Moore algorithm to divide the network into groups. In the TNBN gene regulatory network, there were 352 groups showing a modularity value of 0.825, and the largest group contained 1,241 vertices and 2,421 edges. On the other hand, there were 456 groups showing a modularity value of 0.820 in the TPBN gene regulatory network, with the largest group containing 1,153 vertices and 2,377 edges. In the TNBN gene regulatory network, the largest and second largest groups were connected most frequently ([Figure 1](#F1){ref-type="fig"}), whereas the second and third largest groups were connected most frequently in the TPBN gene regulatory network ([Figure 2](#F2){ref-type="fig"}).

It is known that gene regulatory networks in nature generally satisfy the power law. The distributions of vertex degrees were expected to follow the power law precisely, as defined by *P(k)* \~ *k^--r^*, where r is an exponential factor. Using log-transformed values, we performed a regression analysis on the observed vertex degree and density values of the two gene regulatory networks ([Figure 3](#F3){ref-type="fig"}, [Supplementary Table 1](#S1){ref-type="supplementary-material"}, available online). The slopes in [Supplementary Table 1](#S1){ref-type="supplementary-material"} are the estimated -r values. We noted that the results adequately satisfied the power-law distribution.

In addition, to confirm the subtype-specific clinical relevance, the subset of patients was selected by the status of ER, PR, and HER2 for analysis by Cox proportional hazard regression. Survival analyses were performed on three genes (*CLOCK*, *RAPGEF6*, and *ZDHHC20*), and the hazard ratio and *p*-value are shown in [Supplementary Table 2](#S2){ref-type="supplementary-material"} (available online). The analysis on the three genes revealed that the HER2-negative, ER-positive, and PR-positive groups had meaningful hazard ratios in both univariate and multivariate analyses. In the multivariate survival analysis, the survival rate tended to decrease with a higher expression of *CLOCK*, *ZDHHC20*, and *RAPGEF6*, with hazard ratios of 1.76, 1.54, and 1.51, respectively ([Table 6](#T6){ref-type="table"}).

DISCUSSION
==========

In network analysis, the most important feature is the hub vertex distribution. The TNBN and TPBN gene regulatory networks both showed a scale-free characteristic. This means that, unlike a random network, the TNBN gene regulatory network could be easily destroyed if the hub vertices were attacked. Among the TNBN gene regulatory network hub vertices, the most interesting genes were *RAPGEF6* and *ZDHHC20*. Because these genes are cancer related, they were consistently observed in TNBNs only in the centrality analysis. Draper and Smith \[[@B12]\] have reported that *ZDHHC20* was associated with cellular transformation and cell proliferation, but to the best of our knowledge, its relationship to breast cancer has thus far not been fully elucidated. In this situation, *ZDHHC20* may be a targetable hub vertex in TNBNs. In addition, *RAPGEF6* is known to convert GDP into GTP in the Ras-related proteins Rap1 and Rap2, which are cell-junction related proteins \[[@B13]\]. Activated Rap1 interacts with JamA, Bag3, Afadin, Riam, and RapL to regulate cadherin and integrin, which are connected to the cell junction and extracellular matrix \[[@B14]\]. Thus, if we want to identify changes in cell-to-cell interactions in TNBNs, it is essential to study *RAPGEF6*.

*CLOCK* was at the top of all three centrality analyses of TPBN. Interestingly, in TNBNs, *CLOCK* had 5 degrees, with an eigenvector and betweenness centrality values of 0.003 and 215085.373, respectively. These results show that even though TNBN may not be affected by hormonal dysregulation, its oncogenic property may affect its genesis. The result that higher expression of *CLOCK*, *ZDHHC20* and *RAPGEG6* related to lower survival rate also support the importance of the *CLOCK*, *ZDHHC20*, and *RAPGEF6* genes in each network group. In addition, the *ASXL2*, *CCNT1*, and *NCOA2* genes were also frequently observed in the centrality analysis in both groups. These genes are well-known in tumorigenesis \[[@B15][@B16][@B17]\]. Thus, by conducting a thorough network analysis, we can find not only well-known genes but also genes that are not as well known in cancers. In fact, in the DEG analysis, except for *RAPGEF6*, we could find no other genes showing a meaningful *p*-value (Bonferroni) between the two groups ([Supplementary Table 3](#S3){ref-type="supplementary-material"}, available online). In addition, we compared these genes using 100 normal and 1,084 cancer samples. The genes *CCNT1* and *ASXL2* showed a *p*-value of less than 0.001 (Bonferroni), whereas the other genes showed a *p*-value of 1. Therefore, the DEG analysis using cancer and normal samples suggests that the important genes found from the network analysis cannot be found in the DEG analysis ([Supplementary Table 4](#S4){ref-type="supplementary-material"}, available online).

Through network analysis, we have attempted to understand the physiology of TNBNs. The TNBN and TPBN gene regulatory networks showed similar network statistics, with both having similar network densities, diameters, average vertex-to-vertex distance values, and scale-free network characteristics. However, the TNBN gene regulatory network was less clustered than the TPBN gene regulatory network, albeit showing a similar modularity. In addition, the hub vertices were different in both groups. Although we could not conduct specific analyses on each cluster in the TNBN gene regulatory network, we were able to find some oncogenes through the centrality analyses.
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###### Supplementary Table 1

Regression analysis of observed vertex degree and density values

###### Supplementary Table 2

Cox regression of important hub genes in subset groups

###### Supplementary Table 3

Differentially expressed gene analysis for observed genes

###### Supplementary Table 4

Differentially expressed gene analysis for observed genes in the normal and cancer samples

![Cluster analysis of the triple-negative breast neoplasm gene regulatory network using the Clauset-Newman-Moore algorithm. The largest group (blue) and the second largest group (sky-blue) are connected the most frequently.](jbc-20-240-g001){#F1}

![Cluster analysis of the triple-positive breast neoplasm gene regulatory network using the Clauset-Newman-Moore algorithm. The second largest group (red) and the third largest group (green) are connected the most frequently.](jbc-20-240-g002){#F2}

![Regression analysis of the observed vertex degree and density values. (A) Regression analysis of degree exist in TN has slope -2.823, adjusted R^2^ 0.882, and *p*\<0.001 which satisfy the power-law distribution. (B) Regression analysis of degree exist in TP has slope -2.727, adjusted R^2^ 0.897, and *p*\<0.001 which satisfy the power-law distribution.\
Degree exist in TN=triple-negative breast neoplasm group; Degree exist in TP=triple-positive breast neoplasm group.](jbc-20-240-g003){#F3}

###### Demographics of the triple-positive and triple-negative breast neoplasm patients

![](jbc-20-240-i001)

  -------------------------------------------------------------------------------------------------
  Characteristics   Triple-negative (n = 115)\   Triple-positive (n = 97)\   All (n = 212)\
                    No. (%)                      No. (%)                     No. (%)
  ----------------- ---------------------------- --------------------------- ----------------------
  Stage                                                                      

   I                19 (16.5)                    9 (9.3)                     28 (13.2)

   II               72 (62.6)                    56 (57.8)                   128 (60.4)

   III              19 (16.5)                    30 (30.9)                   49 (23.1)

   IV               2 (1.8)                      1 (1.0)                     3 (1.4)

   NA               3 (2.6)                      1 (1.0)                     4 (1.9)

  Age (yr)^\*^      54.73 (42.94--66.52)         59.98 (45.88--74.08)        57.09 (43.98--70.20)

  Status                                                                     

   Alive            103 (89.6)                   87 (89.6)                   190 (89.6)

   Dead             12 (10.4)                    10 (10.4)                   22 (10.4)

  NAC                                                                        

   Yes              0000                         4 (4.1)                     4 (1.9)

   No               114 (99.1)                   93 (95.9)                   207 (97.6)

   NA               1 (0.9)                      0000                        1 (0.5)

  Margin status                                                              

   Positive         3 (2.6)                      4 (4.2)                     7 (3.3)

   Negative         102 (88.7)                   81 (83.5)                   183 (86.3)

   Close            4 (3.5)                      1 (1.0)                     5 (2.4)

   NA               6 (5.2)                      11 (11.3)                   17 (8.0)

  Race                                                                       

   White            67 (58.3)                    63 (64.9)                   130 (61.3)

   Black            32 (27.9)                    8 (8.3)                     40 (18.9)

   Asian            8 (6.9)                      5 (5.2)                     13 (6.1)

   NA               8 (6.9)                      21 (21.6)                   29 (13.7)
  -------------------------------------------------------------------------------------------------

NAC=neoadjuvant chemotherapy; NA=not available.

^\*^Median (range).

###### Gene regulatory network statistics of triple-negative and triple-positive breast neoplasms

![](jbc-20-240-i002)

  Network statistics                     TNBN          TPBN
  -------------------------------------- ------------- -------------
  Vertices                               10,237        8,930
  Total edges                            17,773        15,223
  Maximum geodesic distance (diameter)   28            29
  Average geodesic distance              8.635109      8.649705
  Graph density                          0.000339225   0.000381835

TNBN=triple-negative breast neoplasm; TPBN=triple-positive breast neoplasm.

###### Degree centrality results for triple-negative and triple-positive breast neoplasms

![](jbc-20-240-i003)

  TNBN        TPBN              
  ----------- ------ ---------- ----
  *ASXL2*     38     *CLOCK*    39
  *GTF2A1*    38     *REST*     32
  *RAPGEF6*   38     *ATP5D*    30
  *ZDHHC20*   35     *TGFBR2*   28
  *CCNT1*     33     *ASXL2*    27
  *PDGFRB*    32     *STRN*     26
  *REST*      31     *RBM27*    25
  *TAOK1*     31     *RIF1*     25
  *RIF1*      30     *CCNT1*    25
  *ATP5D*     30     *ZEB2*     25

TNBN=triple-negative breast neoplasm; TPBN=triple-positive breast neoplasm.

###### Betweenness centrality results for triple-negative and triple-positive breast neoplasms

![](jbc-20-240-i004)

  TNBN        TPBN                       
  ----------- ------------- ------------ -------------
  *ZDHHC20*   2593718.407   *CLOCK*      1256280.673
  *RAPGEF6*   2147541.505   *GYPC*       938225.682
  *ZNF192*    1835667.961   *HIC1*       922622.728
  *GTF2A1*    1468223.374   *REST*       890485.116
  *RIF1*      1437912.482   *ATP5D*      812258.220
  *ATP5D*     1369994.673   *FAM108A1*   794508.449
  *ASXL2*     1366586.056   *GTF2A1*     773790.744
  *REST*      1339309.745   *TRAPPC5*    772846.398
  *CCNT1*     1198033.135   *ASXL2*      759382.681
  *GMCL1*     1040959.614   *CCDC12*     686844.284

TNBN=triple-negative breast neoplasm; TPBN=triple-positive breast neoplasm.

###### Eigenvector centrality results for triple-negative and triple-positive breast neoplasms

![](jbc-20-240-i005)

  TNBN        TPBN               
  ----------- ------- ---------- -------
  *ASXL2*     0.019   *CLOCK*    0.016
  *GTF2A1*    0.017   *CCNT1*    0.013
  *REST*      0.016   *REST*     0.012
  *CCNT1*     0.014   *ASXL2*    0.010
  *ZDHHC20*   0.014   *STRN*     0.009
  *UHMK1*     0.013   *NCOA2*    0.009
  *RAPGEF6*   0.012   *UHMK1*    0.008
  *NCOA2*     0.010   *EXOC6B*   0.007
  *LMTK2*     0.009   *RC3H2*    0.006
  *TAOK1*     0.009   *SHPRH*    0.006

TNBN=triple-negative breast neoplasm; TPBN=triple-positive breast neoplasm.

###### Cox regression based on clinical variables and hub genes

![](jbc-20-240-i006)

  Clinical variable       Univariate Clinical variable   Multivariate                           
  ----------------------- ------------------------------ -------------- ----------------------- ----------
  Age at diagnosis (yr)   1.250 (1.081--1.445)           0.002          1.423 (1.137--1.782)    0.002
  Stage                                                                                         
   I                      Reference                                     Reference               
   II                     1.516 (0.800--2.871)           0.201          1.225 (0.523--2.868)    0.640
   III                    2.645 (1.349--5.187)           0.004          2.792 (1.115--6.987)    0.028
   IV                     4.737 (1.990--11.289)          \< 0.001       5.431 (1.443--20.433)   0.012
  ER                                                                                            
   Positive               Reference                                     Reference               
   Negative               1.582 (1.034--2.420)           0.034          1.205 (0.437--3.323)    0.718
  PR                                                                                            
   Positive               Reference                                     Reference               
   Negative               1.674 (1.119--2.505)           0.012          1.831(0.687--4.879)     0.226
  HER2                                                                                          
   Positive               Reference                                     Reference               
   Negative               0.313 (0.170--0.576)           \< 0.001       0.465 (0.240--0.898)    0.022
  *CLOCK*                 1.523 (1.238--1.874)           \< 0.001       1.779 (1.297--2.440)    \< 0.001
  *RAPGEF6*               1.184 (1.000--1.402)           0.050          1.508 (1.108--2.053)    0.009
  *ZDHHC20*               1.148 (0.974--1.352)           0.100          1.565 (1.179--2.079)    0.002

HR=hazard ratio; CI=confidence interval; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
